5 recruiting, 1 active not recruiting. 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 6 | Recruiting 5, Active not recruiting 1 |
Follow Xaluritamig: new trials by email Literature Review of Xaluritamig trials Research Report on Xaluritamig
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer Xaluritamig - Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 1 | Recruiting | Amgen | 40 | 2026-04-28 | 2026-09-15 |
| Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS) Xaluritamig - Ewing Sarcoma | Phase 1 | Recruiting | Amgen | 50 | 2026-04-08 | 2026-10-29 |
| Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer Xaluritamig, Darolutamide, Abiraterone - Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Phase 1 | Recruiting | Amgen | 60 | 2025-10-07 | 2026-07-02 |
| Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer Xaluritamig, GnRH Antagonist - Prostate Cancer | Phase 1 | Recruiting | Amgen | 40 | 2024-11-25 | 2026-07-31 |
| Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer Xaluritamig - Prostate Cancer, High-risk Biochemical Recurrence | Phase 1 | Active not recruiting | Amgen | 50 | 2024-09-23 | 2026-09-04 |
| Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer AMG 509, Abiraterone, Enzalutamide - Prostate Cancer | Phase 1 | Recruiting | Amgen | 479 | 2020-03-04 | 2026-08-21 |
Prostatic Neoplasms (5) · Bites and Stings (1) · Recurrence (1) · Sarcoma, Ewing (1)
Amgen (6)
United States (6) · Australia (5) · Germany (2) · Switzerland (2) · China (1) · Japan (1) · Portugal (1) · South Korea (1) · Spain (1) · Taiwan (1)
2023 (1)